The New NHS Technology Adoption Centre, NTAC, has re-launched (2011). As part of this process NTAC underwent a comprehensive review and has launched a new set of services to speed up the diffusion of proven technologies across the NHS. These services are based on the considerable expertise and knowledge which has been built up over the last four years and are better aligned with the changing NHS and the current medical technology landscape. Led by CEO Sally Chisholm the new NTAC is building on this base of knowledge and experience with a new team of purposely selected individuals who have the skill and expertise to bring life changing technologies to NHS patients. NTAC is the only organisation that is solely dedicated to the diffusion of proven innovation across the NHS.
NTAC has worked on a number of projects which have enabled medically proven technologies be adopted by the NHS, thus ensuring patients are able to benefit from these innovations.
NTAC believes that examples of innovation are not an issue in the UK but the lack of a ‘pull’ culture within the NHS which often prevents these benefits from being realised.
For example, in March 2011 NICE extended its recommendation on the CardioQ estimating that it could save the NHS in England more than £400m a year. The blood flow monitor, which was originally developed in the UK, reduces the rates of post operative complications as well as reducing the length of critical care and overall hospital stay. However, in order for these patient and financial benefits to be realised it is vital that this innovative technology is widely implemented throughout the NHS.
NICE is recognised as the organisation with the expertise to review the evidence linked to individual technologies but experience shows that NHS organisations also benefit from receiving practical support at the front line of care delivery to enable rapid uptake of this technology. This is where NTAC comes in. In order to actively support the uptake of CardioQ NTAC published a detailed How to Why to Guide™. These Guides provide comprehensive and relevant information for clinicians, managers, key decision makers and other stakeholders on how to implement specific technologies.
Deltex Medical Group Chief Executive, Ewan Phillips said:
“It takes a long time for ideas from the clinicians to feed through to the senior management – the sort of people who can make decisions to do things on a wide scale. That’s always been a problem in the NHS.
“NTAC is vital to widespread adoption of this, and many other, technologies with proven patient benefit and the opportunity to save the NHS millions. Essentially NTAC provides the roadmap which can help the NHS achieve better patient outcomes and also achieve the significant cost savings it is striving for,”
NTAC Chief Executive Sally Chisholm said: “Our work is focused on achieving reproducible benefits in the clinical setting, or more crudely, the real-world. By working with the NHS we can take under-utilised technologies which have shown that they can improve clinical outcomes whilst saving the NHS money and quite literally ‘show’ the NHS how to implement them effectively. Headlines such as ‘savings of £400m per year’ are incredibly exciting, particularly in the current economic climate and with the financial pressures being faced by the NHS. However, the stark reality is that if technologies such as the CardioQ are not implemented throughout the NHS these benefits will never be anything but a headline.”